RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
RenovoRx, Inc. has completed full patient enrollment in its Phase III TIGeR-PaC trial, evaluating its novel intra-arterial gemcitabine therapy delivered via the FDA-cleared RenovoCath device to treat locally advanced pancreatic cancer (LAPC). The trial aims to demonstrate improved overall survival and reduced toxicity compared to standard systemic …